Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BIVINASDAQ:CMMBNASDAQ:LGVNNASDAQ:LMDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIVIBioVie$1.02-4.2%$0.95$0.62▼$7.50$18.84M0.661.84 million shs260,201 shsCMMBChemomab Therapeutics$1.30-4.6%$1.21$0.78▼$2.55$19.56M0.55210,817 shs72,636 shsLGVNLongeveron$1.24-5.3%$1.46$0.77▼$6.40$19.56M0.382.98 million shs97,820 shsLMDXLumiraDx$0.01$0.02▼$1.33$5.10M1.7356.75 million shs132.24 million shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIVIBioVie0.00%-1.46%+17.75%-23.68%+132.05%CMMBChemomab Therapeutics0.00%-4.76%-5.11%-22.62%+36.83%LGVNLongeveron0.00%-8.15%-20.51%-18.42%+19.23%LMDXLumiraDx0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBIVIBioVie2.1642 of 5 stars3.82.00.00.03.00.00.6CMMBChemomab Therapeutics3.7906 of 5 stars3.55.00.00.04.11.71.3LGVNLongeveron3.354 of 5 stars3.65.00.00.01.81.71.3LMDXLumiraDxN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBIVIBioVie 3.50Strong Buy$3.00195.57% UpsideCMMBChemomab Therapeutics 3.00Buy$8.50553.85% UpsideLGVNLongeveron 3.25Buy$8.67598.92% UpsideLMDXLumiraDx 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest LMDX, CMMB, LGVN, and BIVI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025CMMBChemomab TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$11.00 ➝ $10.003/21/2025LGVNLongeveronHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/18/2025BIVIBioVieBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/3/2025LGVNLongeveronHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 6/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBIVIBioVieN/AN/AN/AN/A$2.54 per shareN/ACMMBChemomab TherapeuticsN/AN/AN/AN/A$1.54 per shareN/ALGVNLongeveron$2.23M8.32N/AN/A$2.68 per share0.46LMDXLumiraDx$126.52M0.00N/AN/A($0.33) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBIVIBioVie-$32.12M-$7.91N/A∞N/AN/A-134.07%-93.44%N/ACMMBChemomab Therapeutics-$24.22M-$0.76N/AN/AN/AN/A-101.70%-76.18%8/20/2025 (Estimated)LGVNLongeveron-$21.41M-$6.28N/AN/AN/A-967.49%-142.43%-100.84%N/ALMDXLumiraDx-$447.79M-$1.09N/AN/AN/A-268.45%N/A-77.91%N/ALatest LMDX, CMMB, LGVN, and BIVI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025CMMBChemomab Therapeutics-$0.20-$0.14+$0.06-$0.14N/AN/A5/12/2025Q3 2025BIVIBioVie-$0.32-$0.15+$0.17-$0.15N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBIVIBioVieN/AN/AN/AN/AN/ACMMBChemomab TherapeuticsN/AN/AN/AN/AN/ALGVNLongeveronN/AN/AN/AN/AN/ALMDXLumiraDxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBIVIBioVieN/A16.9416.94CMMBChemomab TherapeuticsN/A4.574.57LGVNLongeveronN/A7.677.67LMDXLumiraDxN/A0.450.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBIVIBioVie4.59%CMMBChemomab Therapeutics46.05%LGVNLongeveron10.01%LMDXLumiraDx9.59%Insider OwnershipCompanyInsider OwnershipBIVIBioVie4.00%CMMBChemomab Therapeutics11.91%LGVNLongeveron19.12%LMDXLumiraDx35.41%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBIVIBioVie1018.56 million17.71 millionNo DataCMMBChemomab Therapeutics2014.36 million12.65 millionNot OptionableLGVNLongeveron2014.93 million12.00 millionNot OptionableLMDXLumiraDx1,210318.55 million205.75 millionNot OptionableLMDX, CMMB, LGVN, and BIVI HeadlinesRecent News About These CompaniesFormer Alere and LumiraDx R&D Chief Nigel Lindner Joins CLEU Diagnostics to Launch Revolutionary LabSimple Diagnostic PlatformMarch 17, 2025 | businesswire.comRoche completes acquisition of LumiraDx’s Point of Care technologyAugust 1, 2024 | pharmabiz.comLumiraDx Ltd LMDXFApril 14, 2024 | morningstar.comLMDX.OJanuary 31, 2024 | reuters.comWhy LumiraDx Shares Are Trading Lower By Over 30%; Here Are 20 Stocks Moving PremarketJanuary 8, 2024 | msn.comWhy Is LumiraDx (LMDX) Stock Down 13% Today?January 8, 2024 | investorplace.comLumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of ...January 5, 2024 | bakersfield.comLumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9thJanuary 5, 2024 | finance.yahoo.comRoche to pick up LumiraDx’s point-of-care tests through $350M dealJanuary 4, 2024 | fiercebiotech.comPositive sentiment towards LMDX reflected in decline in short interestJanuary 4, 2024 | knoxdaily.comRoche (RHHBY) to Acquire LumiraDx's Point of Care TechnologyJanuary 2, 2024 | msn.comRoche Agrees To Purchase Part Of COVID-19 Test Player LumiraDx Diagnostics Platform For $295MJanuary 2, 2024 | benzinga.comWhy LumiraDx Shares Are Trading Lower By 20%; Here Are 20 Stocks Moving PremarketJanuary 2, 2024 | benzinga.comLumiraDx falls on agreement with Roche to sell assetsJanuary 2, 2024 | msn.comRoche to buy part of LumiraDx diagnostics platform for $295 millionDecember 29, 2023 | reuters.comLumiraDx Inc: LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to RocheDecember 29, 2023 | finanznachrichten.deRoche enters into a definitive agreement to acquire LumiraDx's Point of Care technology combining multiple diagnostic modalities on a single platformDecember 29, 2023 | finance.yahoo.comLumiraDx Agrees To Sell Point-of-Care Tech Platform To RocheDecember 29, 2023 | markets.businessinsider.comLumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to RocheDecember 29, 2023 | finance.yahoo.comLumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to RocheDecember 29, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLMDX, CMMB, LGVN, and BIVI Company DescriptionsBioVie NASDAQ:BIVI$1.01 -0.05 (-4.25%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$1.01 -0.01 (-0.89%) As of 05/30/2025 05:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.Chemomab Therapeutics NASDAQ:CMMB$1.30 -0.06 (-4.59%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$1.32 +0.02 (+1.92%) As of 05/30/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.Longeveron NASDAQ:LGVN$1.24 -0.07 (-5.34%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$1.28 +0.04 (+3.23%) As of 05/30/2025 06:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.LumiraDx NASDAQ:LMDXLumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
